Almac reported revenues were up 8% to £325 million in 2013, and pre-tax profits were £19.2 million, up 30%.   Alan Armstrong, chief executive officer of Almac, said, “2013 was an exciting year for us with a major jobs boost in Craigavon as we completed a non-GMP drug development facility and expanded our manufacturing capabilities, announced a £13 million investment in cancer research projects with Queen’s University and signed a $9 million deal with Genomic Health, securing the rights to furthe...